Anti-hVEGF-hIgA2

Human VEGF (bevacizumab) antibody - Human IgA2

ABOUT

Monoclonal human IgA2 antibody against human VEGF

Anti-hVEGF-hIgA2 features the constant region of the human IgA2 isotype and the variable region of bevacizumab. Bevacizumab is a humanized IgG1 monoclonal antibody that targets VEGF, a signaling protein that promotes the growth of new blood vessels. In many cancers VEGF is overexpressed, thereby promoting tumor growth and angiogenesis. The overexpression of VEGF can also lead to vascular disease, particularly in the retina [1]. Bevacizumab neutralizes VEGF and blocks its signal transduction through the VEGF receptors [2, 3]. Consequently, bevacizumab blocks downstream pathways which regulate cell growth and angiogenesis. Bevacizumab displays no antibody-dependent cell-mediated cytotoxicity (ADCC) [4]. Bevacizumab has been approved by the FDA for the treatment of certains types of brain, colorectal, lung, kidney, and ovarian cancers.

IgA2 is found predominantly in secretory lymphoid tissues, where it plays a critical role in mucosal immunity. IgA2 is highly resistant to enzymatic degradation by bacterial proteases, due to a short hinge region. IgA2 displays no complement dependent cytotoxicity (CDC) and low ADCC.

Anti-hVEGF-hIgA2 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with peptide M.

 

References:

1. Ablonczy Z. et al., 2014. Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels. FASEB J. 28:2369-79.
2. Papadopoulos N. et al., 2012. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 15(2):171-85.
3. Ferrara N. et al., 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3(5):391-400.
4. Damiano V. et al., 2007. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. PNAS. 104(30):12468-73.

All products are for research use only, and not for human or veterinary use.

SPECIFICATIONS

Specifications

Target

Vascular endothelial growth factor (VEGF)

Target species

Human

Isotype
hIgG4 (S228P)
kappa
Source
CHO cells
Purification
Protein G
Formulation buffer

0.2 mm filtered solution in a sodium phosphate buffer with glycine, saccharose and stabilizing agents

Preservative
Azide-free
Aggregation

< 5%

Reconstitution buffer
Sterile water
Endotoxin

Negative (tested using EndotoxDetect™ assay)

Tested applications

ELISA

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hVEGF-hIgA2
  • Cat code: 
    hvegf-mab7
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20°C
    Stability: Reconstituted antibody is stable for 1 month when stored at 4 °C and for 1 year when aliquoted and stored at -20 °C. Avoid repeated freeze-thaw cycles.

    Caution:

    • Avoid repeated freeze-thaw cycles

DOCUMENTS

Documents

Anti-hVEGF-hIgA2

Technical Data Sheet

Safety Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?